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Abstract
Persistent pain is a commonly experienced symptom. It affects 25% of community-dwelling older adults and up to 80% of nursing
home residents, and can have a major impact on quality of life and functional capacity. Unfortunately pain in older patients is often
undertreated and misunderstood. Assessment of pain type and severity is important. Most older people, even with moderately
impaired cognition, are able to self-report pain. Validated assessment tools using non-verbal pain cues are available for people with
more advanced cognitive impairment. Management of pain in older people can be challenging. Physiological changes may impact
on pain perception and the pharmacodynamics and pharmacokinetics of medications. Older people are often more sensitive to the
adverse effects of analgesic medications and are at risk of drug–drug interactions due to the presence of co-morbidities and
polypharmacy. In general, analgesic medications should be commenced at low doses, titrated based on effect and tolerability, and
regularly reviewed. Contemporary pain management often utilises multiple analgesics in lower doses to optimise efﬁcacy and avoid
dose-related toxicity. A bio-psycho-social approach to the management of persistent pain, utilising a multidisciplinary team and
including non-drug strategies, may produce the best results. The goal of pain management is not always to eliminate pain, since this
may not be attainable, but rather to enhance function and improve quality of life. This article discusses persistent non-cancer pain in
older people, its assessment and management, and the risks and beneﬁts of pharmacological treatment in this population.
INTRODUCTION
Pain is deﬁned as ‘an unpleasant sensory and emo-
tional experience associated with actual or potential
tissue damage, or described in terms of such damage’.1
The presence of pain over a period of three months or
more is described as persistent or chronic pain. Most
patients with non-cancer persistent pain experience a
mix of both acute painful ﬂares and persistent
pain. Each pain type requires a separate management
strategy.
Acute pain ﬂares are often inﬂammatory in nature
and commonly associated with speciﬁc activities, such
as bending over, lifting awkwardly or muscle overuse.
These may best be treated conservatively with short
periods of rest, heat or cold packs, short-term avoidance
of the ﬂare-inducing activity, and intermittent, short-
term use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) if the individual can tolerate them. Recent
studies have suggested that paracetamol may be ineffec-
tive in acute low back pain.2
Persistent pain is more commonly associated with a
pro-inﬂammatory, cytokine-mediated mechanism,
enhancing sensory neural input from the periphery
which the brain interprets as pain.3 Persistent pain is
often described in terms of somatosensory input and
categorised as neuropathic rather than nociceptive.4
NSAIDs are usually ineffective and associated with sig-
niﬁcant toxicity.5
The pathophysiology, presentation and outcomes of
persistent pain in older adults differ from younger peo-
ple. This is thought to be driven by the process of
homeostenosis, which is the diminished ability to effec-
tively respond to the stress of persistent pain.6 The out-
comes of persistent pain in the elderly may be observed
as changes in quality of life, loneliness, depression and
ability to self-care, which may result in inability to cope
at home and admission to residential care. Yet persistent
pain may respond to lifestyle change such as increased
movement, weight loss, healthy diet, stopping smoking
and reducing alcohol intake. This article provides an
overview of persistent pain in older people and its man-
agement.
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PREVALENCE OF PERSISTENT PAIN
Pain is not inevitable with ageing, but many chronic
health conditions are associated with painful symptoms,
for example arthritis, osteoporosis and diabetes, and
these may affect quality of life and impair function.
Chronic low back pain is one of the most common and
potentially disabling chronic pain condition affecting
older adults. Unfortunately, pain in older patients is
often undertreated and misunderstood.7
The prevalence of pain varies. For example, persistent
pain has been reported in 25% of community-dwelling
older adults,8 45–80% of nursing home residents,9,10 and
53.5% of patients aged >70 years admitted to general
medical wards.11 More females than males report persis-
tent pain.12 In an Australian population-based survey,
peak prevalence of persistent pain occurred in the 80–
84 year age group (31%) in females, and the 65–69 year
age group in men (27%).12
Many older patients function quite well despite per-
sistent pain, while others function poorly. Age-related
comorbidities and functional decline often exist indepen-
dently of pain, so the unique impact of persistent pain
can be difﬁcult to identify.13
PHYSIOLOGICAL CHANGES IN THE OLDER
PERSON
Ageing is associated with physiological changes that
may impact on the perception of pain and the pharma-
codynamics of analgesic medications. There appears to
be a signiﬁcant reduction in the number and function of
peripheral nociceptive neurons with increasing age.14
Sensory thresholds for thermal and vibrational stimuli
are increased and there is a decrease in Pacini corpuscles
(a type of mechanoreceptor) and in Meissner’s or Mer-
kle’s disks (free nerve endings). There is impairment of
descending inhibitory pathways reducing endogenous
analgesic response.15 There is also a decrease in the den-
sity of myelinated nerves and an increase in abnormal
or degenerating ﬁbres producing slower conduction veloc-
ity. In the brain and spinal cord there is a loss of neurons in
the dorsal horn and thalamus and altered cerebral evoked
responses. There is also a reduction in neurotransmitters,
including noradrenaline, acetylcholine, gamma-aminobu-
tyric acid (GABA) and serotonin.16 The impact of these
changes is variable. While they may be expected to
decrease the pain experience in older people,17,18 they gen-
erally don’t appear to do so. This could be because the tem-
poral experience of persistent pain increases higher -level
responses to nociception in the brain.
Ageing is also associated with changes that can
impact on the pharmacokinetics of analgesic medica-
tions.19 Older patients, especially those aged 75 years
and over, frequently present with relative increases in
fat mass and decreases in muscle mass and body water,
producing important changes to the distribution of
drugs within the body. Renal function usually declines
from around the age of 40, at a rate of about 1% or
1 mL/min/year reduction in creatinine clearance. The
ageing liver may prolong the clearance of some drugs,
although liver function tests are often within normal
limits.20
The consequences of pharmacodynamic and pharma-
cokinetic changes are difﬁcult to quantify, but may
increase sensitivity to pharmacological interventions and
risk of side effects. This may result in a requirement for
lower doses; however, analgesics should always be
titrated according to response and tolerability.19
CHALLENGES IN THE PROVISION OF PAIN
MANAGEMENT FOR OLDER PEOPLE
There are major challenges involved in pain manage-
ment in the elderly. These include:
• the myth that having pain is ‘natural’ with increas-
ing age
• managing pain in the context of comorbidity
• lack of congruence between patient’s and care-
giver’s perceptions of pain
• under-reporting and perceived reliability of report-
ing of pain
• sensory and cognitive impairment
• fears of addiction to analgesics
• risks and fears of polypharmacy
• caregiver’s belief systems.
In a survey of people living with chronic pain, a
range of barriers to effective pain management were
identiﬁed, including perceived failure of doctors to
take pain seriously or treat pain effectively, lack of
transportation to doctor or pharmacy and lack of home
caregivers to assist with administration and manage-
ment of medication. Patients with communication
problems and increased psychological stressors (e.g.
anxiety, distress, depression, anger) had poorer pain
control.21
The presence of neurologic diseases like strokes,
dementia and movement disorders may effect a patient’s
ability to report, describe and manage pain,20 and
adhere to often complex medication regimens.22
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PAIN ASSESSMENT
Undue reliance is often placed on unidimensional pain
assessments, usually relating to pain intensity. While
these are relatively easy and quick to administer, they
require a degree of visual and aural acuity, attention
and cognitive function that is often impaired in older
people. Many patients express difﬁculty using or
understanding numerical scales such as the 11-point
(0–10) pain-intensity scale and prefer a word-based
assessment (no pain, mild, moderate, severe, extreme)
such as the Pain Thermometer.23 Multidimensional
assessments such as the Brief Pain Inventory24 examine
not only pain intensity, but also the nature, affect, sensation
and location of pain. However, these assessments can be
time-consuming and difﬁcult to administer.
Pain assessment in the presence of cognitive impair-
ment or dementia can be challenging because self-
reporting may be considered unreliable. However, older
people, even with moderately impaired cognition, are
often able to use self-reporting tools to rate their pain.25
For people with more advanced cognitive impairment,
tools such as the PAINAD (Pain Assessment in
Advanced Dementia)26 and Checklist on Nonverbal Pain
Indicators (CNPI)27,28 can be used to help assess non-
verbal pain cues such as breathing rate, vocalisation,
body language and consolability. Information about
comprehensive pain assessment tools for both cogni-
tively intact and impaired older patients can be found at
the Geriatric Pain website (http://www.geriatricpain.org;
accessed 19 December, 2015).
DRUG THERAPY CHOICES IN OLDER PEOPLE
Pharmacological management of pain is commonly
employed, but should not be seen as the only option.
There is limited evidence from well-designed controlled
trials in older people, especially the frail elderly, to
guide drug therapy. A structured approach for the treat-
ment of persistent pain is advocated based upon the
World Health Organisation analgesic ladder, although
there is little evidence supporting this approach. It is a
pragmatic approach based upon the increased risk of
toxicity with increased levels of intervention, and the syn-
ergism that may be obtained from the multiple levels of
pharmacological input when concurrently used.
No analgesic agent will completely stop pain. The
myth of the pain-killer is just that: a myth. Efﬁcacy of
analgesic medications is measured by their ability to
reduce pain scores, with most clinical trials assessing a
signiﬁcant reduction as a decrease in pain score by 50%.
Numbers needed to treat (NNT) and Numbers needed
to harm (NNH) have been calculated from clinical trials
often performed over relatively short time periods in
samples that are unrepresentative of the elderly popula-
tion, so it is uncertain how these apply in ‘real world’
therapeutics.
Of greater clinical importance is the increase in func-
tion associated with analgesic therapy and occurrence of
adverse effects, often not identiﬁed in clinical trials, par-
ticularly in the elderly population.
PARACETAMOL
For many years paracetamol has been considered the
initial and ongoing pharmacotherapy of choice for per-
sistent pain because of its effectiveness and good safety
proﬁle in therapeutic doses.7,20,29–31 Paracetamol is not a
potent analgesic so is unlikely to make a major impact
on persistent pain, and recent observational cohort stud-
ies have raised questions about its safety,32 with small
increases noted in relative rates of mortality and risk of
cardiovascular, gastrointestinal and renal adverse effects
reported. However, these studies were not able to
ensure that patients were not co-administering NSAIDs
where the risk from such adverse events has been well
demonstrated. Until this is better clariﬁed it is reason-
able to continue to recommend paracetamol, around the
clock, at doses up to 4 g/day. It is recommended that
paracetamol should be avoided or used in lower doses
in people with signiﬁcant liver disease or who are
severely malnourished or very underweight (e.g. less
than 50 kg).33
NSAIDS
Regular use of cyclo-oxygenase (COX)-selective or
non-selective NSAIDs are generally not recommended
for long-term management of persistent pain in older
people29–31 and older patients are at increased risk of
gastrointestinal (GI: bleeding and peptic ulceration),
cardiovascular (hypertension, myocardial and cere-
brovascular) and renal adverse effects. The COX-2
selective NSAIDs such as meloxicam and celecoxib are
associated with lower risk of upper GI bleeds.8
Most signiﬁcant adverse effects of NSAIDs are associ-
ated with medium to long-term treatment courses. As
such, NSAIDs are generally only recommended for
ﬂare-like inﬂammatory pain in patients at low risk of
cardiovascular and gastrointestinal adverse events. They
should be used for the shortest period of time possible
and with gastro-protective cover if necessary, and then
discontinued until the next painful ﬂare.34,35
© 2016 Society of Hospital Pharmacists of Australia Journal of Pharmacy Practice and Research (2016) 46, 1–8
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WEAK OPIODS
The weak opioid analgesic tramadol has dual opioid
and monoaminergic activity, but serotoninergic adverse
effects seem poorly tolerated in the elderly.31 Tramadol
also interacts with many drugs used to treat comorbid-
ity in the older person. As yet there is little experience
in the elderly,36 and controversy about the analgesic
efﬁcacy,35 of the new dual-effect opioid tapentadol,
and other analgesic options should be chosen36 until
more evidence is available. Other weak opioids such
as codeine and dextropropoxyphene are not recom-
mended in the elderly due to poor beneﬁt-to-risk
ratio.8
STRONG OPIOIDS
Strong opioid analgesics, despite being widely used, are
generally not recommended for long-term use in older
people,29–31 due to limited evidence for effectiveness
and increased risk of toxicity.37 A signiﬁcant proportion
of patients who start opioid therapy discontinue it due
to adverse effects or lack of efﬁcacy; however, some will
experience clinically signiﬁcant pain relief.37
Opioid metabolites may accumulate in the elderly
brain, leading to sedation and confusion. Long-term opi-
oid therapy (longer than 6–8 weeks) is associated with
increased risk of dependence, tolerance, opioid-induced
hyperalgesia and suppression of gonadotropin-releasing
hormone secretion.
Short-acting opioids are not recommended for persis-
tent pain because they are usually active for only
3–4 h,38 and the neuroplastic changes in sensitisation
associated with persistent pain seem, in part, driven by
ﬂuctuation in pain levels over time.
A recent review39 concluded that there is little to
choose between buprenorphine, fentanyl, hydromor-
phone, morphine and oxycodone in the frail elderly
patient despite opioids differing in pharmacokinetic and
pharmacodynamic properties, with variance in excretion
in impaired renal function and some having active
metabolites.
Opioids should be commenced at low dose and
gradually titrated. The maximum recommended opioid
dose in adults with persistent non-cancer pain is
100 mg oral morphine equivalent daily dose (OMEDD),
as most opioid-overdose related deaths occur at doses
greater than this.40 Elderly patients may only tolerate
smaller doses. Many prescription opioids are available
in doses greatly in excess of this. It is important to
recognise that the relative potency of a 25 micrograms/h
fentanyl patch is 90 mg OMEDD; 40 mg twice daily con-
trolled release (CR) oxycodone has an OMEDD of
120 mg; and 16 mg CR hydromorphone has an OMEDD
of 80 mg.
Opioid clearance is often reduced in the elderly,
requiring longer dose intervals. Opioids are not consid-
ered very potent in neuropathic pain. Only oxycodone
has been demonstrated to be of value in neuropathic
pain, although the evidence supporting this is conﬂict-
ing.41
Buprenorphine is a potent analgesic usually adminis-
tered in a weak transdermal dose form. Transdermal
administration appears useful except in the conditions
of high heat and humidity (e.g. in northern Australia)
where transdermal patches often fail to adhere to skin.
Many ambulant elderly patients also ﬁnd it difﬁcult to
apply patches without assistance. The buprenorphine
patches are considered a weak opioid because the 5
microgram/h patch is considered to have an OMEDD of
~9 mg, and the 20 microgram/h patch an OMEDD of
~36 mg.
While fear of addiction (deﬁned as drug craving,
drug seeking behaviours and continued use despite
known harms)8 is often identiﬁed as a barrier to pain
treatment, published evidence suggests that addiction to
opioids for pain management is rare.42
CO-ANALGESIC OR ANALGESIA
MODULATION AGENTS
Tricyclic antidepressants (TCAs)
Tricyclic antidepressants have effects on serotonin and
noradrenergic reuptake. They are usually not recom-
mended for older people because they add signiﬁcantly
to ‘anticholinergic burden’, causing confusion or delir-
ium, as well as being associated with postural
hypotensive changes increasing risk of falls.43,44 How-
ever, small doses (e.g. 5–10 mg amitriptyline or nor-
triptyline) may be helpful for some patients if
tolerated, especially for ‘shooting’ neuropathic pain
types45 which are often resistant to treatment and dis-
tressing to patients.
Serotonin-noradrenaline reuptake inhibitors
(SNRIs)
Two SNRIs are used as analgesia-modulation agents:
venlafaxine and duloxetine. Duloxetine appears to be
reasonably well tolerated in the elderly at doses of
30 mg/day and has been more widely used in persistent
pain, especially of neuropathic origin, painful diabetic
Journal of Pharmacy Practice and Research (2016) 46, 1–8 © 2016 Society of Hospital Pharmacists of Australia
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peripheral neuropathy and pain associated with
ﬁbromyalgia.46–48 Venlafaxine exhibits dose-dependant
pharmacology.49 At doses <75 mg/day it would appear
to function as a serotonin reuptake inhibitor; which has
little effect on pain. As the dose increases, noradrenaline
reuptake inhibitor effects increase, and at doses
>150 mg antidopaminergic effects begin to dominate.
Patients may need to take up to 225 mg for analgesic
beneﬁt, thus side effect burden may be excessive for
older patients.50,51
Anti-epileptic drugs (AEDs)
Sodium channel inhibitor and ‘pentinoid’ AEDs have
been used in the management of neuropathic pain for
many years. Carbamazepine is the ﬁrst-line drug of
choice for managing neuropathic facial pain like trigemi-
nal neuralgia.52 Therapy with this agent is complicated
by the need for dose adjustments following auto-
induction of metabolism by CYP3A4 and its adverse
effects on balance in the elderly.
Gabapentin and pregabalin have the best evidence
to support their use in neuropathic pain, although
most clinical studies have been relatively short, usually
of 2–4 months duration, in well-deﬁned neuropathic
pain syndromes such as post-herpetic neuralgia and
painful peripheral diabetic neuropathy.53,54 Their side
effects may be signiﬁcant, affecting eyesight, balance,
weight gain and cognitive function, as well as less
common problems such as peripheral oedema and
mood disturbance. Clinical trials support careful dose
titration of these medications: an initial dose of 25 mg
of pregabalin or 100 mg gabapentin each evening and
slowly increasing the dose in 25 mg or 100 mg incre-
ments, respectively.19 The onset of analgesia is often
slow, so there appears to be little need to drive rapid
dose titration, which may be associated with poor side
effect tolerance and subsequent discontinuation by the
patient.
Other antiepileptic medications have been used in
pain (e.g. phenytoin, lamotrigine, topiramate and val-
proate) despite the relative paucity of evidence to sup-
port them. Side effects are a major limiting factor to
their use.55
Topical agents
Topical NSAIDs have been suggested as a possible
ﬁrst-line treatment of musculoskeletal acute pain ﬂares
in the elderly because of their low levels of toxicity.19
Topical application of lignocaine (in the 5% patch for-
mulation) or capsaicin cream at a concentration >0.1%
have been used in the management of neuropathic
pain syndromes,56 although many older patients do
not have the dexterity to appropriately utilise these
agents.
Lignocaine 5% patches are particularly useful when
they act as an effective barrier between skin and cloth-
ing for touch-evoked hyperalgesia in post-herpetic neu-
ralgia, a condition commonly seen in older patients.
They do not demonstrate signiﬁcant absorption, so
adverse effects are minimal. Some guidelines suggest
they be considered as third-line agents,57 while others
suggest early use because of their low risk of adverse
effects.8,19
Topical capsaicin may cause initial discomfort if
applied in error to damaged skin or mucous mem-
branes. Cessation of capsaicin due to side effects
appears more common with repeated low-dose applica-
tion of the cream compared to a new 8% patch formula-
tion (15% compared to 1%).58,59 Neither lignocaine
patches nor capsaicin are available on the Pharmaceuti-
cal Beneﬁts Scheme in Australia, so cost may inhibit
their use.
COMBINATION PHARMACOTHERAPY
Evidence suggests that polypharmacy (more than ﬁve
medicines) is becoming more common and is associated
with increased morbidity and mortality in the elderly.60
However, contemporary pain management usually uti-
lises multiple analgesics to attempt addressing the com-
plexity of persistent pain yet avoiding dose-related
toxicity with any single agent.19 Many of these anal-
gesic options are ones that are recommended to be
avoided or used with caution in the frail elderly.61
There is therefore an obvious dilemma for treating any
individual elderly patient. Ayres62 proposed a six-step
process to overcome such barriers in older patients (Fig-
ure 1).
MULTIDISCIPLINARY NON-
PHARMACOLOGICAL MANAGEMENT
A bio-psycho-social approach to the management of per-
sistent pain,63 utilising a multidisciplinary team, appears
to produce the best results for chronic pain manage-
ment, including in older patients (Figure 2).
The goal of pain management is not always a reduc-
tion in pain intensity, since this may not be attainable,
but rather an enhancement of function and improve-
ment in health-related quality of life. The utilisation of
combined pharmacological and non-pharmacological
treatments delivered by a multidisciplinary team
© 2016 Society of Hospital Pharmacists of Australia Journal of Pharmacy Practice and Research (2016) 46, 1–8
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appears to be the most effective management option.29
This includes patient education about persistent pain
and pain management strategies using a mix of context-
appropriate and paced movement, building psychologi-
cal coping though an acceptance-based approach,
developing mindfulness stress reduction and facilitating
activities of daily living through occupational therapy
support to break the fear/avoidance cycle (Figure 3),
which may lead to physical deconditioning, anxiety,
depression and worsening pain.
Step
Ayres, Warmington + Reid 2012
1 Comprehensive pain assessment e.g. SOCRATES
S – site   O  - onset  C – character R –
radiation A  -associations  T- time course 
E  -exacerbation/relieving S severity
2 Review the patient’s problem list Medication reconciliation
-full medication list (Rx, OTC, CAMs), 
-full history of medical conditions,
3 Establish patient’s treatment goals Address potential unrealistic expectations
Agree patient focussed goals
4 Identify barriers/problems associated 
with initiating and adhering to 
therapy
Cognitive impairment, sensory 
impairment, socio-demographic factors, 
health beliefs
5 ‘Start low and go slow’ when 
initiating analgesics
Avoid start low and stay low
Have therapeutic plan if AEs occur or 
treatment goals not met 
6 Assess for effects and outcomes Identify and clarify potential AEs with 
patient and create a plan to address 
them
Figure 1 Six-step process.
The Biopsychosocial approach to persistent pain management
(after Gatchel et al 2007)
Biological Psychological Social
Central processes
Biological Cognitive
Somatic Affective
Peripheral processes
Autonomic  Endocrine
Immune systems
Genetic predispositions
Efferent Feedback
Afferent Feedback
Activities of daily living
Environmental stressors
Interpersonal relationships
Family environment
Social support/isolation
Social expectations
Cultural factors
Medicolegal/insurance 
issues
Previous experiences
Work history
Figure 2 Biopsychosocial pain management model.
Fear/avoidance model
Figure 3 9Pain fear/avoidance cycle.
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CONCLUSION
Pain management in older patients can be complicated,
with fears of adverse effects, over- and under-use of
medications and patient non-adherence competing for
priority with the basic humanitarian need to reduce
pain and suffering. Understanding this complexity and
applying it to the care of the individual patient, using
both pharmacological and non-pharmacological
approaches, appears to offer the best way forward.
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